A Systematic Review of Economic Evidence in Hepatitis C: An Overview of Cost, Utility and Cost-Effectiveness Data

Abstract

A349 transformed to common logarithms. Costs are stated in € (1€ = 25.5CZK). Results: A total 100 patients (about 10-15% of all HIV treated in the Czech Republic) were included. The mean age was 41.9 years (range 23-71), time since diagnosis 5.8 years (range 1-26), and period of assessment 30.5 months. Average total annual costs were highest for CD4+ <200 (22,905€ ; p<0.05) vs. CD4+ 200-499 (17,801€) and CD4+ >500 (17,043€). HIV medication accounted for the majority of costs in all three subgroups (range 62% in CD4+ <200 to 88% in CD4+ >500). Patients with a disease duration of >10 years had highest annual costs of 22,841€ (p<0.05) compared to 15,783€ (duration 5-10 years) and 16,777€ (<5 years). HIV-medication accounted for the majority of costs here as well (from 70% to 88%; NS). In this analysis 17 % of costs in patients with disease duration of >10 years were due to hospitalization vs. 5 % in both other groups (NS). ConClusions: Similarly to published literature, we found highest costs in patients with low CD4+ lymphocytes and longer disease duration.